|
|
|
|
Vol. 61, Issue 4, 729-737, April 2002
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan (H.U., Y.K., D.K.Y., A.C., E.M., H.E.); Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (H.U.); Precursory Research for Embryonic Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan (Y.K.); and Department of Pharmacology and Physiology, School of Medicine and Dentistry, University of Rochester, Rochester, New York (M.F.W., M.W.A)
| |
Abstract |
|---|
|
|
|---|
The L-type amino acid transporter 1 (LAT1) is an
Na+-independent neutral amino acid transporter subserving
the amino acid transport system L. Because of its broad substrate
selectivity, system L has been proposed to be responsible for the
permeation of amino acid-related drugs through the plasma membrane. To
understand the mechanisms of substrate recognition, we have examined
the LAT1-mediated transport using a Xenopus laevis
oocyte expression system. LAT1-mediated
[14C]phenylalanine uptake was strongly inhibited in a
competitive manner by aromatic-amino acid derivatives including
L-dopa,
-methyldopa, melphalan, triiodothyronine, and
thyroxine, whereas phenylalanine methyl ester, N-methyl
phenylalanine, dopamine, tyramine, carbidopa, and droxidopa did not
inhibit [14C]phenylalanine uptake. Gabapentin, a
-amino acid, also exerted a competitive inhibition on LAT1-mediated
[14C]phenylalanine uptake. Although most of the compounds
that inhibited LAT1-mediated uptake were able to induce the efflux of
[14C]phenylalanine preloaded to the oocytes expressing
LAT1 through the obligatory exchange mechanism, melphalan,
triiodothyronine, and thyroxine did not induce the significant efflux.
Based on the experimental and semiempirical computational analyses, it is proposed that, for an aromatic amino acid to be a LAT1 substrate, it
must have a free carboxyl and an amino group. The carbonyl oxygen
closer to the amino group needs a computed charge of
0.55~
0.56 and must not participate in hydrogen bonding. In addition, the hydrophobic interaction between the substrate side chain and the substrate binding site of LAT1 seems to be crucial for the substrate binding. A substrate, however, becomes a blocker once Connolly accessible areas become large and/or the molecule has a high calculated logP value, such as those for melphalan, triiodothyronine, and thyroxine.
| |
Introduction |
|---|
|
|
|---|
System
L is an amino acid transporter that transports large neutral amino
acids in an Na+-independent manner (Oxender and
Christensen, 1963
; Christensen, 1990
). It is a major route through
which living cells take up branched or aromatic amino acids from
extracellular fluids. In addition, system L, as a basolateral membrane
transport system, plays important roles in the absorption of amino
acids through the epithelial cells of the small intestine and renal
proximal tubules (Christensen, 1990
). System L is also essential in the penetration of amino acids through the blood-brain barrier and the
placenta barrier (Christensen, 1990
). Because of its broad substrate
selectivity, system L is proposed to transport not only naturally
occurring amino acids but also amino acid-related compounds such as
L-dopa, a therapeutic drug for Parkinsonism; melphalan, an
anticancer phenylalanine mustard; triiodothyronine and thyroxine, two
thyroid hormones; gabapentin, an anticonvulsant; and
S-(1,2-dichlorovinyl)-L-cysteine, a
neurotoxic cysteine conjugate (Goldenberg et al., 1979
; Christensen, 1990
; Lakshmanan et al., 1990
; Blondeau et al., 1993
; Patel et al.,
1993
; Su et al., 1995
; Gomes and Soares-da-Silva, 1999
). The precise
examination on the interaction of these compounds with system L
transporters, however, has been difficult using system L activity
endogenous to cultured cells or tissue preparations, particularly for
the compounds with low transport rate.
By means of expression cloning, we isolated a cDNA encoding the first
isoform of system L transporter from C6 rat glioma cell cDNA library
(Kanai et al., 1998
). The transporter designated as L-type amino acid
transporter 1 (LAT1) is a predicted 12-transmembrane protein and is
unique because it requires an additional single membrane-spanning
protein, the heavy chain of 4F2 cell surface antigen (4F2hc), for its
functional expression in the plasma membrane (Kanai et al., 1998
). LAT1
mediates Na+-independent amino acid exchange and
prefers large neutral amino acids with bulky or branched side chains
for its substrates. Although the expression of 4F2hc is ubiquitous, the
expression of LAT1 is restricted to certain tissues such as brain,
placenta, and testis (Kanai et al., 1998
). LAT1 is highly expressed in
cultured cells and malignant tumors. presumably to support their
continuous growth (Sang et al., 1995
; Wolf et al., 1996
; Kanai et al.,
1998
). Recently, we and others demonstrated that LAT1 and 4F2hc
proteins are present in the luminal and abluminal membranes of brain
capillary endothelial cells and mediate the permeation of amino acids
through the blood-brain barrier (Duelli et al., 2000
; Kageyama et al., 2000
; Matsuo et al., 2000
; Killian and Chikhale, 2001
). After the
identification of LAT1, transporters structurally related to LAT1 have
been found to be associated with 4F2hc or another single
membrane-spanning subunit rBAT (related to b0,+ amino acid
transporter) (Verrey et al., 2000
). These transporters include systems
asc, y+L, x
; Verrey et
al., 2000
). LAT2 is more ubiquitously expressed than LAT1 and
transports not only large neutral amino acids but also small neutral
amino acids (Pineda et al., 1999
; Rossier et al., 1999
; Segawa et al.,
1999
).
A remarkable characteristic of system L, as mentioned above, is its broad substrate selectivity, which enables the transporter to accept amino acid-related compounds. Because of this characteristic, system L is regarded as a drug transporter responsible for the determination of pharmacokinetics of amino acid-related drugs. To understand the mechanisms of substrate recognition, we have expressed system L transporter LAT1 in Xenopus laevis oocytes and examined LAT1-mediated transport of amino acids and amino acid-related compounds.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
L-[14C]Phenylalanine,
L-[14C]tyrosine,
[14C]dopamine,
[125I]triiodothyronine, and
[125I]thyroxine were purchased from PerkinElmer
(Boston, MA). L-[14C]dopa
was from American Radiolabeled Chemicals, Inc (St. Louis, MO).
Gabapentin and droxidopa were provided by Parke-Davis Pharmaceutical Research (Ann Arbor, MI) and Sumitomo Pharmaceutical Co. Ltd (Osaka, Japan), respectively. Other chemicals were purchased from Sigma (St.
Louis, MO). The chemical structures of amino acid related drugs used in
the present investigation are shown in Fig.
1.
|
X. laevis Oocyte Expression.
Capped cRNAs for
rat LAT1 and rat 4F2hc were synthesized in vitro using T7 RNA
polymerase, as described elsewhere (Kanai et al., 1998
). X. laevis oocyte expression studies were performed as described
elsewhere with minor modifications (Kanai and Hediger, 1992
;
Utsunomiya-Tate et al., 1996
). Briefly, oocytes were treated with
collagenase A (2 mg/ml) (Roche Molecular Biochemicals, Mannheim Germany) for 30 to 50 min at room temperature in
Ca2+-free medium (82.5 mM NaCl, 2 mM KCl, 1 mM
MgCl2, and 5 mM HEPES, pH 7.5) to remove
follicular layer and then maintained in modified Barth's solution (88 mM NaCl, 1 mM KCl, 0.33 mM
Ca(NO3)2, 0.41 mM
CaCl2, 0.82 mM MgSO4, 2.4 mM NaHCO3, and 10 mM HEPES, pH 7.5). For
coexpression of LAT1 and 4F2hc in X. laevis oocytes,
defolliculated oocytes were injected with LAT1 cRNA (15 ng) and 4F2hc
cRNA (10 ng) to give a molar ratio of 1:1 (Kanai et al., 1998
). After
injection of cRNAs, the oocytes were incubated in the modified Barth's
solution at 18°C until uptake was measured.
Uptake Measurement.
Uptake measurements were performed 2 days after injection of cRNA. Groups of six to eight oocytes were
washed in the uptake solution and then incubated in 500 µl of uptake
solution (100 mM choline chloride, 2 mM KCl, 1.8 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, and 5 mM Tris, pH 7.4) containing 0.5 to 2.0 µCi/ml of radiolabeled compounds for 15 min at 22°C (Kanai et al., 1998
). The
oocytes were then washed five times with ice-cold uptake solution. The
radioactivity was counted by liquid scintillation spectrometry, and the
values are expressed in picomoles per oocyte per minute.
1] (Apiwattanakul et al., 1999Efflux Measurements.
Oocytes expressing LAT1 and 4F2hc were
incubated for 30 min in the uptake solution containing 20 µM
L-[14C]phenylalanine (2 µCi/ml)
to load the oocytes with
L-[14C]phenylalanine (Kanai et al.,
1998
). The oocytes were then washed five times with ice-cold uptake
solution and transferred individually to separate wells of 48-well
plates containing 150 µl of uptake solution with or without addition
of 100 µM test compounds. After 5 min of incubation, 125 µl of
incubation medium was removed from each well and mixed with an equal
volume of 20% SDS. The oocytes were transferred to scintillation vials
and solubilized with 10% SDS. The radioactivity in the medium and the
remaining radioactivity in the oocytes were measured. The values were
expressed as percentage radioactivity (radioactivity of medium or
oocytes / (radioactivity of medium + radioactivity of oocytes oocytes)
(Kanai et al., 1998
).
Computational Analysis. Chemical structures were drawn with CS Chem-Draw Ultra (version 6.0; Cambridge Soft Corporation, Cambridge, MA) and copied into CS Chem3D Pro (version 6.0.1; Cambridge Soft Corporation). For each molecule, a molecular mechanics minimization was performed with a root-mean-square of 0.001. The CS MOPAC PRO application was used to compute, at the semiempirical Austin-model 1 (AM1) level of theory with a root-mean-square of 0.001, a theoretical dipole (Debye) and charge for the various atoms. Upon which, the property server was used to compute calculated logP (ClogP) and the Connolly accessible area (Å2).
Statistical analysis. Values are shown as means ± S.E.M. (n = 6-8). Statistical differences were analyzed by Student's unpaired t test.
| |
Results |
|---|
|
|
|---|
Transport Activity.
As shown in Fig.
2A, X. laevis oocytes that
express LAT1 and 4F2hc exhibited a high level of
L-[14C]phenylalanine
uptake compared with water-injected control oocytes. Uptake was
time-dependent and exhibited a linear dependence on incubation time up
to 30 min; all subsequent uptake measurements were conducted for 15 min
and the values are expressed as picomoles per oocyte per minute.
LAT1-mediated transport was calculated as the difference between uptake
by oocytes expressing LAT1 and 4F2hc and that by water-injected control
oocytes. As shown in Fig. 2B, LAT1-mediated
L-[14C]phenylalanine
uptake was saturable and followed Michaelis-Menten kinetics with
Km values of 12.5 ± 3.1 µM
(mean ± SEM of four separate experiments). Because the transport
of L-[14C]phenylalanine
was not dependent on Na+ or
Cl
(data not shown), transport measurements
were performed under sodium-free conditions in subsequent experiments.
|
Inhibition of LAT1-Mediated Uptake by Amino Acid-Related
Compounds.
LAT1-mediated
L-[14C]phenylalanine uptake (20 µM) was measured in the presence of 2 mM concentrations of nonlabeled
compounds. As shown in Fig. 3A,
L-[14C]phenylalanine uptake was
markedly inhibited by tyrosine, L-dopa, 3-O-methyldopa,
-methylphenylalanine,
-methyltyrosine,
-methyldopa, and gabapentin. Triiodothyronine, thyroxine, and
melphalan also inhibited
L-[14C]phenylalanine
uptake (Fig. 3B). In contrast, N-methylphenylalanine, phenylalanine methyl ester, carbidopa, droxidopa, tyramine, and dopamine did not inhibit
L-[14C]phenylalanine
uptake (Fig. 3A). As shown in Fig. 4A and
B, tyrosine and L-dopa were competitive
inhibitors of
L-[14C]phenylalanine
uptake. 3-O-Methyldopa,
-methyldopa,
-methyltyrosine, gabapentin, triiodothyronine, thyroxine, and melphalan were also competitive inhibitors of LAT1-mediated
L-[14C]phenylalanine
uptake (data not shown). The Ki values
for these compounds are provided in Table
1. The semiempirical (AM1) computational data for amino acids and amino acid-related compounds examined in the
present study are provided in Table 2.
|
|
|
|
Transport of Amino Acid-Related Compounds.
Among the compounds
that inhibited LAT1-mediated
L-[14C]phenylalanine uptake, we
examined whether L-dopa, triiodothyronine, and thyroxine,
which are available as radiolabeled compounds, are transported by LAT1.
As shown in Fig. 5A,
L-[3H]dopa as well as
L-[14C]tyrosine were transported by
LAT1 as high-affinity substrates (Table 1). The
Km value for each coumpound was
roughly close to the Ki value (Table
1). In contrast, [14C]dopamine was not a
substrate for LAT1. As shown in Fig. 5B, oocytes expressing LAT1
exhibited significantly higher uptake of
[125I]triiodothyronine and
[125I]thyroxine than control oocytes, although
the levels of uptake were low compared with amino acid substrates.
Uptake of [125I]triiodothyronine and
[125I]thyroxine by LAT1 was not detected when
uptake measurements were performed on ice, confirming the
transporter-mediated uptake of these compounds (data not shown).
|
Characteristics of LAT1-Mediated Amino-Acid Efflux.
In
experiments in which oocytes were loaded with
L-[14C]phenylalanine and the efflux
of loaded radioactivity induced by extracellularly applied nonlabeled
phenylalanine was measured, we detected efflux of radioactivity
confirming the previous observation indicating the obligatory exchange
of substrate amino acids mediated by LAT1 (Fig.
6A). Almost half of the loaded
radioactivity appeared in the extracellular medium in 30 min in the
presence of 100 µM phenylalanine in the extracellular medium. The
efflux of loaded
L-[14C]phenylalanine induced by 100 µM phenylalanine applied extracellularly was almost linear for up to
15 min (Fig. 6A); hence, efflux was measured for 10 min, and values are
expressed as percentage of radioactivity loaded into oocytes in
subsequent measurements. The efflux of loaded
L-[14C]phenylalanine induced by
extracellularly applied phenylalanine followed Michaelis-Menten
kinetics with a Km value of 14.0 µM (Fig. 6B). In addition, the efflux of
L-[14C]phenylalanine was
not dependent on extracellular Na+ or
Cl
(data not shown).
|
LAT1-Mediated Efflux Induced by Amino Acid-Related Compounds.
The amino acid-related compounds that inhibited LAT1-mediated
L-[14C]phenylalanine uptake were
investigated to determine whether they induce the efflux of loaded
L-[14C]phenylalanine when applied
extracellularly. As shown in Fig. 7A, the
efflux of loaded
L-[14C]phenylalanine was induced by
the extracellularly applied tyrosine, L-dopa,
3-O-methyldopa,
-methylphenylalanine,
-methyltyrosine,
-methyldopa, and gabapentin (100 µM). Significant efflux was not
induced by carbidopa, triiodothyronine, thyroxine, and melphalan (Fig.
7, A and B).
|
| |
Discussion |
|---|
|
|
|---|
LAT1 is selective for large neutral
-amino acids with branched
or aromatic side chains as substrates (Kanai et al., 1998
). Because
N-methylphenylalanine and phenylalanine methyl ester had little effect on LAT1-mediated
L-[14C]phenylalanine
uptake, it is suggested that both
-amino and
-carboxyl groups are
recognized by the substrate-binding site of LAT1 (Fig. 3A). In
agreement with this conclusion, tyramine and dopamine, both of which
lack
-carboxyl groups, and carbidopa, an N-amino
derivative of L-
-methyldopa (Fig. 1), failed
to inhibit LAT1-mediated transport (Fig. 3A).
The semiempirical (AM1) computational data in Table 2 provides
additional insight and support to the experimental conclusions. In the
examination of the results for carbidopa and phenylalanine methyl
ester, it is observed that the relative charges (Besler et al., 1990
)
residing on the carbonyl oxygen atoms (
0.3811 and
0.3924;
0.2805
and
0.3608, respectively) are substantially different from those for
the molecules that inhibit
L-[14C]phenylalanine uptake, such
as tyrosine and gabapentin (
0.5635 and
0.5948, respectively).
Because all of the molecules investigated possess a chiral center,
except gabapentin, the two resonance-stabilized carbonyl oxygens in the
computed gas-phase molecules reside in chemically distinct environments
and are therefore enantiotopic. Hence, from the calculated values in
Table 2, it can be concluded that the resonance stabilized carbonyl
oxygen closer in proximity to the amino group must have a computed
charge of (
0.55 ~
0.56), except for gabapentin (
0.5948);
not only is gabapentin a nonchiral
-amino acid but it also contains
a cyclohexane ring that experience ring-flips (Fig. 1) (Su et al.,
1995
), unlike all of the aromatic amino acid analogs that possess a
weak field effect on the amino nitrogen (Wempe, 2001
). In the case of
N-methyl phenylalanine, the amino charge of
0.22 is far
from ideal (
0.27) for the aromatic amino acids and therefore not
recognized. Hence, both carbonyl oxygen charge (
0.55 ~
0.56)
and amino charge (
0.27) are required for an aromatic amino acid to be
a substrate of LAT1. This is in contrast to the system T transporter
TAT1, which recognizes aromatic amino acids as anions (Kim et al.,
2001
).
LAT1 accepts
-methyl amino acids as substrates (Figs. 3A and 7A;
Table 1), indicating that the binding site of LAT1 can accommodate
methyl substituents on the
-carbon. It is therefore suggested that
binding to the substrate binding site is dependent on the interaction
of positive and negative charges of
-amino and
-carboxyl groups
with the substrate-binding site and that an interaction between the
-carbon and the binding site is not essential. This is consistent
with the observation that, as mentioned above, gabapentin, which is not
an
-amino acid, is a substrate for LAT1 (Figs. 3A and 7A).
Comparison of the charges on the
-carbons of L-dopa
versus
-methyldopa (
0.2904 and
0.1990), and tyrosine versus
-methyltyrosine (
0.2872 and
0.1952) (Table 2) shows that the
relative values are consistent with the conclusion that the
-carbon
binding interaction is not the most essential interaction. In fact, the
Ki values provided in Table 1 have the
trend tyrosine < L-dopa <
-methyltyrosine <
-methyldopa, which is the same trend
observed for the carbonyl oxygen's charge (
0.5635 <
0.5633 <
0.5579 <
0.5558) but not for the
-carbons.
Droxidopa, a
-hydroxy derivative of L-dopa (Fig. 1),
failed to interact with LAT1 (Fig. 3A). A possible explanation for this is that a loss in electron-density associated with the carboxylic acid
(due to the intramolecular hydrogen bonding interaction between
-hydroxyl group and
-carboxyl group) decreases droxidopa's
ability to interact with the binding site, although it is still
possible that the
-hydroxy group apparently interferes with the
substrate binding.
The affinity of LAT1 for phenylalanine, tyrosine, and
L-dopa, which have zero, one, or two phenolic hydroxyl
groups (Fig. 1), varies with the number of phenolic hydroxyl groups. As
shown in Table 1, the Km value of
L-dopa is higher than those of phenylalanine and
tyrosine. Consistent with this, the Ki
value of L-dopa is higher than that of tyrosine
(Table 1). This cannot be attributed to the bulkiness of the
3'-position of tyrosine, because 3-O-methyldopa, a methoxy
derivative of L-dopa with more bulky moiety at
the 3'-position, inhibited LAT1-mediated transport more strongly than
L-dopa (Fig. 3A). The
Ki values provided in Table 1,
instead, have the trend tyrosine < 3-O-methyldopa < L-dopa, which is the same trend observed for
calculated ClogP values (0.0984 >
0.0524 >
0.4986) (Table 2). Therefore, it is suggested that hydrophobicity is
an important determinant for the binding of amino acid side chains to
the substrate-binding site of LAT1 (Yunger and Cramer, 1981
; Chollet et
al., 1997
). Hydrophobic interactions between substrate side chains and
the substrate-binding site apparently play critical roles in the
stability of the substrate binding.
Consistent with the observations on system L in cultured cells or
membrane-vesicle preparations, LAT1-mediated transport is inhibited by
thyroid hormones, such as triiodothyronine and thyroxine, and by
melphalan (Fig. 3B) (Goldenberg et al., 1979
; Vistica, 1980
; Lakshmanan
et al., 1990
; Blondeau et al., 1993
; Prasad et al., 1994
). It was
previously reported that IU12/ASUR4, a X. laevis homolog of
LAT1, accepts thyroid hormones as substrates (Ritchie et al., 1999
).
These amino acids with bulky side chains are competitive inhibitors of
LAT1-mediated transport with Ki values
comparable with those of L-dopa and other
phenylalanine derivatives (Table 1). Therefore, the binding site of
LAT1 can accommodate bulky side chains, such as those of thyroid
hormones and melphalan. Interestingly, the
Ki value of triiodothyronine is among
the lowest of the compounds tested. Hydrophobic interactions between
the side chain of triiodothyronine and the substrate-binding site of
LAT1 are proposed to be strong enough to promote this high affinity.
In contrast to substrate amino acids, which exhibit high levels of
uptake, the transport rates of
[125I]triiodothyronine and
[125I]thyroxine are low despite their high
affinity for the binding site of LAT1 (Fig. 5). As discussed below, the
transport rate of melphalan is also low. With the organic anion
transporter OAT1, it was reported that the transport rate of
nonsteroidal anti-inflammatory drugs is inversely correlated with the
hydrophobicity of the compounds (Apiwattanakul et al., 1999
). For OAT1,
hydrophobic interactions are also regarded as important determinants of
substrate binding (Apiwattanakul et al., 1999
). Compounds with strong
hydrophobic interactions with the binding site possess high affinity
for the binding site, whereas the transport rate would, in contrast, be retarded, perhaps because of slow dissociation from the substrate binding site. Another possible explanation for their slow rate of
transport is the bulkiness of their side chains. Thyroid hormones and
melphalan have bulky side chains, which may interfere with conformational changes of the transporter protein associated with the
translocation of substrates.
To evaluate whether compounds that inhibit LAT1-mediated transport are
also transportable substrates or nontransportable blockers, we
performed efflux measurements. Phenylalanine applied to the outside of
oocytes induced the efflux of loaded
L-[14C]phenylalanine (Fig. 6).
Efflux was dependent on incubation time and on the concentration of
extracellularly applied L-phenylalanine (Fig. 6). The
Km value of extracellular
L-phenylalanine required to induce the efflux of
loaded
L-[14C]phenylalanine was
close to that of
L-[14C]phenylalanine
uptake, which is consistent with the concept of obligatory exchange for
transport mediated by LAT1. Taking advantage of this exchange property,
it is possible to evaluate whether compounds accepted by the binding
site of LAT1 are transported or not by examining their ability to
induce the efflux of loaded L-[14C]phenylalanine.
This strategy is, in particular, useful for compounds for which
radiolabeled forms are not available (Apiwattanakul et al., 1999
;
Fukasawa et al., 2000
; Kanai et al., 2000
). As shown in Fig. 7A,
phenylalanine, tyrosine, and L-dopa, which are
transportable substrates of LAT1 (Fig. 5A), induce the efflux of loaded
L-[14C]phenylalanine,
whereas carbidopa, which does not inhibit
L-[14C]phenylalanine
uptake (Fig. 3A), does not induce efflux of loaded L-[14C]phenylalanine.
3-O-Methyldopa,
-methylphenylalanine,
-methyltyrosine,
-methyldopa, and gabapentin also induced the efflux of loaded L-[14C]phenylalanine,
indicating that these compounds are transported by LAT1 (Fig. 7A).
In contrast, triiodothyronine, thyroxine, and melphalan did not induce detectable levels of efflux of loaded L-[14C]phenylalanine (Fig. 7B). This observation is consistent with the results from the uptake measurement in which the transport rates of [125I]triiodothyronine and [125I]thyroxine were low compared with amino acid substrates (Fig. 5B). It is proposed that melphalan, along with thyroid hormones, is not transported at high rates. Triiodothyronine, thyroxine, and melphalan are thus not regarded as good substrates; indeed, they behave more like blockers even though they may be transported at low rates. It is interesting to note that melphalan, triiodothyronine, and thyroxine have relatively large Connolly accessible areas (>500Å2), and have computed ClogP values greater than 1.80: 2.114, 5.672, and 6.795, respectively (Table 2).
Based on the results from the present study, we propose a model for the
substrate-binding site of LAT1 (Fig. 8).
Because both positive and negative charges at the
-carbon are
required for transport, the substrate-binding site of LAT1 is proposed
to possess the recognition sites that depend on electronic interactions
with the peptide backbone of LAT1 (Fig. 8). The side chain-binding site
is presumably associated with hydrophobic residues because hydrophobic
interaction is critical for the binding of substrate amino acid side
chains (Fig. 8). We proposed previously a model for the substrate
binding for the system y+L transporter y+LAT1
which is structurally related to LAT1 and mediates
Na+-dependent transport of neutral amino acids
and Na+-independent transport of basic amino
acids (Kanai et al., 2000
). In the model, the side chain binding site
is equipped with a positive charge recognition site. It is proposed
that, although the substrate binding site of y+LAT1
possesses similar spatial profile to that of LAT1, y+LAT1
has acquired the additional mechanism for positive charge recognition
in the course of evolution (Kanai et al., 2000
).
|
Although our present study is based on the correlative relationships
obtained in the somewhat nonphysiological X. laevis oocyte expression system, the structure-activity relationship data still allow
the use of semiempirical (AM1) computational analysis to predict
LAT-mediated transport. For an aromatic amino acid to be a LAT1
substrate, it must have a free carboxyl group. The carbonyl oxygen
nearer the amino group needs a computed charge of (
0.55 ~
0.56) and must not participate in hydrogen bonding. Furthermore, the
molecule must contain an amino group with a computed nitrogen charge
of ~
0.27. These factors seem to be required for a molecule to
be a substrate, whereas a substrate becomes a blocker once Connolly
accessible areas become large (>500 Å2) and/or
the molecule has a calculated ClogP > 2.0, such as those for
melphalan, triiodothyronine, and thyroxine.
| |
Acknowledgments |
|---|
We are grateful to Hisako Ohba and Michi Takahashi for technical assistance.
| |
Footnotes |
|---|
Received August 30, 2001; Accepted January 7, 2002
This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Japan Society for the Promotion of Science, the Promotion and Mutual Aid Corporation for Private Schools of Japan, the Japan Science and Technology Corporation, Japan Foundation for Applied Enzymology, and the Japan Health Sciences Foundation.
Address correspondence to: Dr. Yoshikatsu Kanai, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan. E-mail: ykanai{at}kyorin-u.ac.jp
| |
Abbreviations |
|---|
LAT1, L-type amino acid transporter 1; 4F2hc, 4F2 heavy chain; AM1, Austin-model 1; ClogP, calculated logP.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. C. Cundy, S. Sastry, W. Luo, J. Zou, T. L. Moors, and D. M. Canafax Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin J. Clin. Pharmacol., December 1, 2008; 48(12): 1378 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Mich and W. A. Horne Alternative Splicing of the Ca2+ Channel {beta}4 Subunit Confers Specificity for Gabapentin Inhibition of Cav2.1 Trafficking Mol. Pharmacol., September 1, 2008; 74(3): 904 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Koopmans, J. W. B. de Groot, J. T.M. Plukker, E. G.E. de Vries, I. P. Kema, W. J. Sluiter, P. L. Jager, and T. P. Links 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation J. Nucl. Med., April 1, 2008; 49(4): 524 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Haase, R. Bergmann, F. Fuechtner, A. Hoepping, and J. Pietzsch L-Type Amino Acid Transporters LAT1 and LAT4 in Cancer: Uptake of 3-O-Methyl-6- 18F-Fluoro-L-Dopa in Human Adenocarcinoma and Squamous Cell Carcinoma In Vitro and In Vivo J. Nucl. Med., December 1, 2007; 48(12): 2063 - 2071. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al. Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Summerfield, K. Read, D. J. Begley, T. Obradovic, I. J. Hidalgo, S. Coggon, A. V. Lewis, R. A. Porter, and P. Jeffrey Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 205 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li and A. R. Whorton Functional characterization of two S-nitroso-L-cysteine transporters, which mediate movement of NO equivalents into vascular cells Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1263 - C1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang, Z. Dai, C. Barbacioru, and W. Sadee Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance Cancer Res., August 15, 2005; 65(16): 7446 - 7454. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gu, C. J. Villegas, and J. X. Jiang Differential Regulation of Amino Acid Transporter SNAT3 by Insulin in Hepatocytes J. Biol. Chem., July 15, 2005; 280(28): 26055 - 26062. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tomi, M. Mori, M. Tachikawa, K. Katayama, T. Terasaki, and K.-i. Hosoya L-Type Amino Acid Transporter 1-Mediated L-Leucine Transport at the Inner Blood-Retinal Barrier Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2522 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Z. Su, M. R. Feng, and M. L. Weber Mediation of Highly Concentrative Uptake of Pregabalin by L-Type Amino Acid Transport in Chinese Hamster Ovary and Caco-2 Cells J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1406 - 1415. [Abstract] [Full Text] [PDF] |
||||
|
|